<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00363714</url>
  </required_header>
  <id_info>
    <org_study_id>SIRNA 0401</org_study_id>
    <secondary_id>AGN211745</secondary_id>
    <nct_id>NCT00363714</nct_id>
    <nct_alias>NCT00495742</nct_alias>
  </id_info>
  <brief_title>A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sirna Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Allergan</source>
  <brief_summary>
    <textblock>
      The purpose of this study will be to assess the safety and tolerability and dose-limiting
      toxicity of a single intravitreal injection of Sirna-027 (AGN211745) and to assess the
      anatomical changes in the retina, changes in CNV, and changes in visual acuity. Escalation to
      the next dose cohort will be completed following minimum of 2 weeks follow-up. Patients will
      be monitored intensively for three months, and then followed-up for safety up to 24 months
      post-injection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Time frame 3 months: Baseline/Day 1, Day 2, Day 7, Day 14, Day 28, Day 56, Day 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity using the Diabetic Retinopathy Study chart</measure>
    <time_frame>Time frame 24 months: Screening, Day 1, Day 2, Day 7, Day 14, Day 28, Day 56, Day 84, Month 6, Month 9, Month 12, Month 18, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP</measure>
    <time_frame>Time frame 24 months: Screening, Day 1, Day 2, Day 7, Day 14, Day 28, Day 56, Day 84, Month 6, Month 9, Month 12, Month 18, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OCT</measure>
    <time_frame>Time frame 3 months: Screening, Day 7, Day 14, Day 28, Day 56, Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluorescein Angiography (FA)</measure>
    <time_frame>Time frame 24 months (Screening, Day 7, Day 14, Day 28, Day 84 and Month 24)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <condition>Choroidal Neovascularization</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravitreal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN211745</intervention_name>
    <description>100microgram single intravitreal injection</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Sirna-027</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN211745</intervention_name>
    <description>200microgram single intravitreal injection</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Sirna-027</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN211745</intervention_name>
    <description>400microgram single intravitreal injection</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Sirna-027</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN211745</intervention_name>
    <description>800microgram single intravitreal injection</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Sirna-027</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN211745</intervention_name>
    <description>1200microgram single intravitreal injection</description>
    <arm_group_label>5</arm_group_label>
    <other_name>Sirna-027</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN211745</intervention_name>
    <description>1600microgram single intravitreal injection</description>
    <arm_group_label>6</arm_group_label>
    <other_name>Sirna-027</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active AMD with Subfoveal CNV (classic and/or occult CNV)

          -  CNV lesion thickness &gt;/= 250um by OCT assessment

          -  Visual acuity in study eye of &lt;/= 20/100 but not worse than 20/800

          -  Not eligible for or refused standard treatment

        Exclusion Criteria:

          -  Females of childbearing potential

          -  Other causes of CNV including pathologic myopia, the ocular histoplasmosis syndrome,
             angioid streaks, choroidal rupture and multifocal choroiditis

          -  Any intraocular surgery or treatment of AMD with Visudyne within 3 months of study
             entry

          -  CNV lesion &gt;/= 12 MPS disc area
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2006</study_first_submitted>
  <study_first_submitted_qc>August 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <last_update_submitted>August 14, 2008</last_update_submitted>
  <last_update_submitted_qc>August 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Therapeutic Area Head</name_title>
    <organization>Allergan, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

